Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

Detección de los marcadores precoces (RUNX/AML1 y ER,/ETV5) de invasión miometrial y mestatatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 9700
Reference: EEBB-I-2010-00375
Duration: 08/02/2010 - 10/08/2010

Ministerio de Ciencia

Oncologia Translacional

IP: Jaume Reventós Puigjaner
Collaborators: Soledad Gallego Melcón, Manuel López Cano, José Placer Santos, Josep Sánchez de Toledo Codina, Joan Morote Robles, Ma Teresa Quiles Pérez, Maria Asuncion Perez Benavente, Eva Colas Ortega, Miguel Segura Ginard, Berta Diaz Feijoo, Manuel Armengol Carrasco, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Marina Rigau Resina, Maria Antonia Arbos Via, Jacques Planas Morin, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 57200
Reference: 2009 SGR 487
Duration: 01/01/2010 - 30/04/2014

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

RTICC - Red Temática de Investigación cooperativa de cáncer

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Ma Teresa Quiles Pérez, Francina Munell Casadesus, Eva Colas Ortega, Enric Trilla Herrera, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Tomàs Pinós Figueras, Rosanna Paciucci Barzanti, Marina Rigau Resina, Carles Xavier Raventós Busquets, Maria Antonia Arbos Via, Jacques Planas Morin, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 350549.54
Reference: RD06/0020/0058
Duration: 02/01/2007 - 31/12/2013

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Sanz Tejo, Marta

Sanz Tejo, Marta

Research technician
Read more
Sergi Martí Beltran

Sergi Martí Beltran

Pneumology
Read more
Polo Figueres, Laura

Polo Figueres, Laura

Multidisciplinary Nursing Research Group
Read more
Paula Granado Martinez

Paula Granado Martinez

Predoctoral researcher
Biomedical Research in Melanoma
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.